[
Abatacept
Inflammation
Polymyalgia rheumatica
Steroids
Therapeutic assessment
[18F] FDG PET/CT
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
26
09
2023
accepted:
01
12
2023
pubmed:
14
12
2023
medline:
14
12
2023
entrez:
14
12
2023
Statut:
ppublish
Résumé
Evaluate the benefit of 2-deoxy-2-[18F]-fluoro-D-glucose ([ This was an ancillary study of ALORS trial (Abatacept in earLy Onset polymyalgia Rheumatica Study) assessing the ability of ABA versus placebo to achieve low disease activity (C-Reactive Protein PMR activity score (CRP PMR-AS) ≤ to 10) without glucocorticoid (GC) at week 12 in patients with early-onset PMR. The patients underwent [ At W12, there was no significant difference according to SUVmax between the ABA and the placebo groups in all ROI. Subgroup analysis according to GC administration demonstrated a significant (p 0.047) decrease in SUVmax within the left sternoclavicular joint ROI in the ABA group (- 0.8) compared to the placebo group (+ 0.6) without GC rescue. Other results did not reveal any significant difference between the ABA and placebo groups. According to combined qualitative scores, there was no significant difference between ABA and placebo groups for the direct comparison analysis and subgroup analysis according to GC rescue. [ The study was approved by the appropriate ethics committee (CPP Sud-Est II Ref CPP: 2018-33), and all patients gave their written informed consent before study enrollment. The protocol was registered on Clinicaltrials.gov (NCT03632187).
Identifiants
pubmed: 38095675
doi: 10.1007/s00259-023-06557-x
pii: 10.1007/s00259-023-06557-x
doi:
Banques de données
ClinicalTrials.gov
['NCT03632187']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1297-1309Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum. 2012;64:943–54.
doi: 10.1002/art.34356
pubmed: 22389040
Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012;71:484–92.
doi: 10.1136/annrheumdis-2011-200329
pubmed: 22388996
Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol Hoboken NJ. 2015;67:2569–80.
doi: 10.1002/art.39333
Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol. 2005;32:65–73.
pubmed: 15630727
Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Direct medical costs of polymyalgia rheumatica. Arthritis Rheum. 2005;53:578–84.
doi: 10.1002/art.21311
pubmed: 16082650
Bonelli M, Radner H, Kerschbaumer A, Mrak D, Durechova M, Stieger J, et al. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial. Ann Rheum Dis. 2022;81:838–44.
doi: 10.1136/annrheumdis-2021-221126
pubmed: 35210264
Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, Richez C, Truchetet M-E, Wendling D, et al. Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial. JAMA. 2022;328:1053–62.
doi: 10.1001/jama.2022.15459
pubmed: 36125471
Palard-Novello X, Querellou S, Gouillou M, Saraux A, Marhadour T, Garrigues F, et al. Value of (18)F-18F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment. Eur J Nucl Med Mol Imaging. 2016;43:773–9.
doi: 10.1007/s00259-015-3287-z
pubmed: 26753600
Devauchelle-Pensec V, Berthelot JM, Cornec D, Renaudineau Y, Marhadour T, Jousse-Joulin S, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016;75:1506–10.
doi: 10.1136/annrheumdis-2015-208742
pubmed: 26929219
Devauchelle-Pensec V. Has the time come for biotherapies in giant cell arteritis and polymyalgia rheumatica? Joint Bone Spine. 2016;83:471–2.
doi: 10.1016/j.jbspin.2016.07.003
pubmed: 27526638
Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation. 2010;121:906–15.
doi: 10.1161/CIRCULATIONAHA.109.872903
pubmed: 20142449
pmcid: 2837465
Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol. 2013;9:731–40.
doi: 10.1038/nrrheum.2013.161
pubmed: 24189842
pmcid: 4277683
Weyand CM, Younge BR, Goronzy JJ. IFN-γ and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol. 2011;23:43–9.
doi: 10.1097/BOR.0b013e32833ee946
pubmed: 20827207
pmcid: 3081721
Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB. Structural analysis of CTLA-4 function in vivo. J Immunol Baltim Md. 1950;2000(164):5319–27.
Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity. 2006;24:233–8.
doi: 10.1016/j.immuni.2006.03.001
pubmed: 16546089
Cron RQ. A signal achievement in the treatment of arthritis. Arthritis Rheum. 2005;52:2229–32.
doi: 10.1002/art.21206
pubmed: 16052533
Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349:1907–15.
doi: 10.1056/NEJMoa035075
pubmed: 14614165
Genovese MC, Becker J-C, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114–23.
doi: 10.1056/NEJMoa050524
pubmed: 16162882
Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A Randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol Hoboken NJ. 2017;69:837–45.
doi: 10.1002/art.40044
Langford CA, Monach PA, Specks U, Seo P, Cuthbertson D, McAlear CA, et al. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener’s). Ann Rheum Dis. 2014;73:1376–9.
doi: 10.1136/annrheumdis-2013-204164
pubmed: 24323392
Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol Hoboken NJ. 2017;69:846–53.
doi: 10.1002/art.40037
Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73:86–94.
doi: 10.1136/annrheumdis-2013-203843
pubmed: 23962455
Salaün P-Y, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, et al. Good clinical practice recommendations for the use of PET/CT/CT in oncology. Eur J Nucl Med Mol Imaging. 2020;47:28–50.
doi: 10.1007/s00259-019-04553-8
pubmed: 31637482
Glaudemans AWJM, de Vries EFJ, Galli F, Dierckx RAJO, Slart RHJA, Signore A. The use of (18)F-18F-FDG-PET/CT/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin Dev Immunol. 2013;2013: 623036.
doi: 10.1155/2013/623036
pubmed: 24027590
pmcid: 3763592
Slart RHJA, Writing group, Reviewer group, Members of EANM Cardiovascular, Members of EANM Infection & Inflammation, Members of Committees, SNMMI Cardiovascular, et al. 18F-FDG-PET/CT/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET/CT Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging. 2018;45:1250–69.
van der Geest KSM, Treglia G, Glaudemans AWJM, Brouwer E, Jamar F, Slart RHJA, et al. Diagnostic value of [18F]18F-FDG-PET/CT/CT in polymyalgia rheumatica: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48:1876–89.
doi: 10.1007/s00259-020-05162-6
pubmed: 33372248
Blockmans D, De Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. RePET/CTitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatol Oxf Engl. 2007;46:672–7.
doi: 10.1093/rheumatology/kel376
Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis. 2004;63:1279–83.
doi: 10.1136/ard.2003.011379
pubmed: 15361387
pmcid: 1754762
Leeb BF, Bird HA, Nesher G, Andel I, Hueber W, Logar D, et al. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT). Ann Rheum Dis. 2003;62:1189–94.
doi: 10.1136/ard.2002.002618
pubmed: 14644857
pmcid: 1754412
Binard A, De Bandt M, Berthelot J-M, Saraux A. Inflammatory Joint Disease Working Group CRI of the French Society for Rheumatology. Usefulness of the disease activity scores for polymyalgia rheumatica for predicting glucocorticoid dose changes: a study of 243 scenarios. Arthritis Rheum. 2007;57:481–6.
doi: 10.1002/art.22630
pubmed: 17394219
Binard A, Lefebvre B, De Bandt M, Berthelot J-M, Saraux A, Club “Rhumatismes et Inflammation.” Validity of the polymyalgia rheumatica activity score in primary care practice. Ann Rheum Dis. 2009;68:541–5.
Cleuziou C, Binard A, De Bandt M, Berthelot J-M, Saraux A. Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice. J Rheumatol. 2012;39:310–3.
doi: 10.3899/jrheum.110866
pubmed: 22174199
Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol. 2011;90:484–94.
doi: 10.1016/j.ejcb.2010.10.007
pubmed: 21145125
Devauchelle-Pensec V, Saraux L, Berthelot JM, De Bandt M, Cornec D, Guellec D, et al. Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable. Rheumatol Oxf Engl. 2018;57:666–70.
doi: 10.1093/rheumatology/kex477
Henckaerts L, Gheysens O, Vanderschueren S, Goffin K, Blockmans D. Use of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica-a prospective study of 99 patients. Rheumatol Oxf Engl. 2018;57:1908–16.
doi: 10.1093/rheumatology/kex376
van der Geest KSM, van Sleen Y, Nienhuis P, Sandovici M, Westerdijk N, Glaudemans AWJM, et al. Comparison and validation of 18F-FDG-PET/CT/CT scores for polymyalgia rheumatica. Rheumatol Oxf Engl. 2022;61:1072–82.
doi: 10.1093/rheumatology/keab483
Sondag M, Guillot X, Verhoeven F, Blagosklonov O, Prati C, Boulahdour H, et al. Utility of 18F-fluoro-dexoxyglucose positron emission tomography for the diagnosis of polymyalgia rheumatica: a controlled study. Rheumatol Oxf Engl. 2016;55:1452–7.
doi: 10.1093/rheumatology/kew202
Saraux A, Le Henaff C, Dernis E, Carvajal Alegria G, Alice Tison, Quere B, et al. Abatacept in the Early-Onset Polymyalgia Rheumatica Study (ALORS): a proof-of-concept randomized trial. Lancet Rhumatol. In press.